Beryl Drugs Limited (BOM:524606)
24.59
+0.75 (3.15%)
At close: Sep 4, 2026
Beryl Drugs Revenue
Beryl Drugs had revenue of 72.97M INR in the quarter ending June 30, 2026, with 52.20% growth. This brings the company's revenue in the last twelve months to 213.23M, up 8.28% year-over-year. In the fiscal year ending March 31, 2026, Beryl Drugs had annual revenue of 188.20M, down -11.00%.
Revenue (ttm)
213.23M
Revenue Growth
+8.28%
P/S Ratio
0.58
Revenue / Employee
n/a
Employees
n/a
Market Cap
124.71M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 188.20M | -23.26M | -11.00% |
| Mar 31, 2025 | 211.46M | -55.83M | -20.89% |
| Mar 31, 2024 | 267.30M | -1.41M | -0.53% |
| Mar 31, 2023 | 268.71M | 122.67M | 84.00% |
| Mar 31, 2022 | 146.04M | 5.11M | 3.62% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.71B |
| Vivanza Biosciences | 1.17B |
| Unjha Formulations | 152.79M |
| Zenith Healthcare | 108.46M |
| Norris Medicines | 76.00M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Colinz Laboratories | 58.11M |
| Ganga Pharmaceuticals | 28.28M |